Key Takeaways
- Atomic Alchemy, Oklo’s subsidiary, obtained its inaugural NRC materials license, permitting isotope handling, processing, and sales from its Idaho facility.
- This regulatory approval opens up an initial revenue channel for the currently pre-revenue parent company through commercial isotope sales.
- The approval doesn’t extend to Oklo’s core advanced nuclear reactor operations — those still require separate NRC authorization before power generation begins.
- Oklo finalized a fresh partnership with the U.S. Department of Energy for its inaugural reactor project at Idaho National Laboratory.
- Shares climbed 4.6% during premarket hours before the company’s quarterly results scheduled for Tuesday evening.
On Tuesday, Oklo achieved a significant regulatory win, albeit with important context. The nuclear technology firm revealed that its wholly-owned subsidiary, Atomic Alchemy (purchased in 2025), has received its first-ever materials license from the Nuclear Regulatory Commission — marking a notable distinction from Oklo’s primary reactor business.
This authorization permits Atomic Alchemy to acquire, maintain, transform, and sell isotopes at its Idaho Falls-based Idaho Radiochemistry Laboratory. The license covers handling up to 2 Curies of Ra-226, plus Co-60 and Am-241 for calibration applications.
Such isotopes are experiencing increased demand across healthcare, scientific research, industrial manufacturing, and national defense sectors. Oklo’s CEO Jacob DeWitte articulated the situation clearly: “Critical isotope demand continues climbing, yet domestic supply capacity stays constrained.”
The near-term commercial implications are tangible. Atomic Alchemy can now initiate revenue-generating isotope sales from its Idaho operation, representing Oklo’s first revenue-producing activity. The parent company currently remains pre-revenue.
Crucially, investors should understand: this isn’t the reactor authorization market observers have been anticipating. Oklo’s advanced fast reactor technology continues navigating the NRC approval pipeline. Until that authorization arrives, electricity sales — the company’s primary long-term revenue model — cannot commence.
License Scope and Details
The NRC issued the authorization following thorough documentation review and physical inspection of the Idaho installation. Atomic Alchemy intends to reclaim and refine decommissioned radium sources — materials historically classified as waste — converting them into valuable feedstock for medical isotope manufacturing, particularly for targeted alpha therapy applications.
Looking ahead, the laboratory serves a broader strategic vision. Atomic Alchemy is advancing plans for a comprehensive multi-reactor isotope production facility featuring up to four Versatile Isotope Production Reactor (VIPR) units, each delivering approximately 15 MWth output capacity.
Tuesday delivered additional positive news. Oklo revealed a new cooperative agreement with the U.S. Department of Energy supporting the engineering, construction, and operational phases of its inaugural reactor at Idaho National Laboratory through the DOE’s Reactor Pilot Program.
Meta Partnership and Financial Results Ahead
Oklo’s nuclear energy vision has secured backing from a major technology player. The firm maintains a collaborative arrangement with Meta Platforms for developing a nuclear energy campus in Ohio’s southeastern region. BofA Securities characterized this as “among the few concrete, binding collaborations currently existing” within the wider nuclear sector.
Shares advanced 4.6% in premarket activity Tuesday as market participants absorbed the developments. Oklo plans to release quarterly financial results following Tuesday’s closing bell.
The company projects commencing commercial nuclear power generation operations during late 2027 or throughout 2028.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
